胰腺癌多种治疗模式的临床疗效对比

Comparison of clinical efficacy of different modalities for treatment of pancreatic cancer

目的:比较不同治疗模式对胰腺癌的疗效。方法:分析2008年1月—2011年2月收治的100例胰腺癌患者资料,其中30例采用单纯手术治疗(手术治疗组),30例采用化疗治疗(化疗组),30例采用手术切除联合化疗治疗(联合治疗组),另10例采取其他治疗方法治疗(其他方法治疗组)。比较各组患者经治疗后的的生存情况,及不良反应发生情况。结果:手术治疗组、化疗组、联合治疗组、其他方法治疗组的中位生存期分别为(13.77±1.44),(11.95±1.60)(17.26±1.44),(2.89±1.46)个月,联合治疗组的生存情况明显优于其余各组(χ2=45.96,P=0.000);联合治疗组的总体不良反应发生率(3.33%)明显低于手术治疗组(26.67%),化疗组(30.00%),其他方法治疗组(30.00%)(χ2=8.178,P=0.04)。结论:应根据胰腺癌患者具体情况选择合适的治疗措施,以手术为主的综合治疗仍是最有效的手段。

Objective： To compare the clinical efficacy of different modalities for treatment of pancreatic cancer. Methods： The clinical data of 100 patients with pancreatic cancer admitted from January 2008 to February 2011 were analyzed. Of the patients, 30 cases underwent surgical resection alone （surgical treatment group）, 30 cases received chemotherapy alone （chemotherapy group）, 30 cases underwent surgical resection plus chemotherapy （combination treatment group） and the remaining 10 cases received other treatment （other treatment group）. The survival status and adverse reactions after treatment among the groups were compared. Results： The median survival time of patients after treatment in surgical treatment group, chemotherapy group, combination treatment group and other treatment group was （ 13.77± 1.44）, （ 11.95_± 1.60）, （17.26-± 1.44）and （2.89± 1.46） months respectively, and the survival status of combination treatment group was significantly better than that of the other three groups （x2=45.96, P=0.000）. The overall incidence of adverse reaction in combination treatment group （3.33%） was significantly lower than that in surgical treatment group （26.67%）, chemotherapy group （30.00%） and other treatment group （30.00%） （x2=8.178, P=0.04）. Conclusion： For pancreatic cancer patients, treatment approaches should vary according to the individual clinical circumstances, but the surgery-based multimodality treatment remains the most effective method.